Summit Therapeutics Inc. — Q1 2021 Form 10-Q
Business and period: Biopharmaceutical company developing novel antibiotics, with a Phase 3 program for ridinilazole to treat and reduce recurrence of C. difficile infection (CDI), and earlier-stage research using its Discuva Platform. This unaudited filing covers the three months ended March 31, 2021; comparisons are with Q1 2020. The company had no approved products and remained research-and-development focused.
Key financial results
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Revenue | $0.2 million | $0.3 million |
| Research and development expense | $18.4 million | $12.9 million |
| General and administrative expense | $4.2 million | $3.6 million |
| Other operating income | $5.4 million | $6.8 million |
| Operating loss | $16.9 million | $9.3 million |
| Net loss | $17.5 million | $6.1 million |
| Loss per share, basic and diluted | $0.21 | $0.09 |
| Net cash used in operating activities | $20.7 million | $5.0 million |
Revenue was solely from the Eurofarma license and commercialization agreement. No product gross margin was reported; the filing does not provide a meaningful commercial-product margin measure.
At March 31, 2021, cash and cash equivalents were $102.2 million, total current assets $125.2 million, total current liabilities $73.1 million, total liabilities $76.4 million, and stockholders’ equity $64.4 million. Current liabilities included a $55.0 million unsecured promissory note payable to Executive Chairman and CEO Robert W. Duggan. The company reported no material off-balance-sheet arrangements. Contractual operating lease obligations totaled $1.4 million.
Changes versus prior period
- Net loss widened by $11.4 million, while operating expenses rose $6.1 million. R&D spending increased primarily from CDI Phase 3 clinical and manufacturing work and related staffing and facilities costs.
- Other operating income declined $1.4 million: BARDA income fell to $1.8 million from $4.9 million as certain work segments reached funding limits, partly offset by increased UK R&D tax credits, to $3.7 million from $1.8 million.
- Other income of $3.3 million in Q1 2020, primarily a foreign-exchange gain, became $0.6 million of other expense in Q1 2021, primarily a foreign-exchange loss.
- Operating cash use increased to $20.7 million from $5.0 million. Financing provided $55.9 million in Q1 2021, mainly from the related-party note and stock-option exercises; cash rose from $66.4 million at year-end 2020 to $102.2 million.
Outlook, risks, and notable items
- Management expected existing cash, funding agreements, R&D tax-credit receivables, and proceeds from a subsequent rights offering to fund current operating plans through Q4 2022. It also said additional capital would be needed to complete all activities associated with the two ridinilazole Phase 3 trials. The company expected ongoing operating losses and warned that financing may not be available on acceptable terms or at all.
- After quarter-end, Duggan’s initial $55.0 million note was rescinded and repaid; a replacement $55.0 million note was issued April 20. On May 12, the company completed a fully subscribed rights offering, raising $75.0 million gross through 14,312,976 shares at $5.24 per share, and used part of the proceeds to repay the replacement note and accrued interest. Duggan purchased 11,365,921 shares and beneficially owned approximately 70.78% after the offering. Shares outstanding were 97,244,567 as of May 12.
- COVID-19 disruptions included remote work, some trial-site enrollment suspensions or slower enrollment, and potential risk of clinical-supply expiration or replacement. The company said these factors could delay development and increase costs; future effects remained uncertain.
- BARDA had committed $62.4 million of funding; $53.9 million had been received and $47.4 million recognized as cumulative income by March 31, 2021. Further funding depended on BARDA exercising its final option and specified milestones.
- The company disclosed correction of an immaterial prior-period error involving deferred tax assets and goodwill; management said no previously filed statements required amendment. Risk factors were reported as unchanged from the 2020 Form 10-K. No material legal proceedings were reported, and disclosure controls were deemed effective.
Important facts for investors to verify
- Clinical-trial enrollment, timing, costs, and the status and expected results of the ridinilazole Phase 3 program, including COVID-19 effects.
- Cash burn and funding runway assumptions, including whether additional financing will be required before the stated Q4 2022 horizon.
- BARDA’s remaining optional funding and the timing and eligibility of UK R&D tax-credit receipts.
- Terms and repayment of the related-party notes, rights-offering proceeds, resulting dilution, and Duggan’s post-offering ownership.
- Potential Eurofarma development milestones and the conditions for future milestone and product-supply payments.